|
|
1.
|
Digoxin significantly improves all-cause mortality in atrial fibrillation patients with severely reduced left ventricular systolic function. MedStar authors:
Year: 2013
Citation: - International Journal of Cardiology. 169(5):e84-6, 2013 Nov 20.
Institution: - MedStar Washington Hospital Center
Department: - Medicine/General Internal Medicine
Medline publication type:
All authors: - Arora S, Badheka AO, Bhalara V, Chothani A, Deshmukh A, Grover PM, Hoosien M, Khalpada D, Lafferty J, Mehta K, Mitrani RD, Patel N, Patel NJ, Rathod A, Savani GT, Shah N, Singh V, Vazzana TJ, Viles-Gonzalez JF
|
|
|
2.
|
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Cunningham, A
- Gallagher, Christopher
- Hofmeyer, Mark
- Srichai, M B
- Swain, Sandra M
Year: 2019
Citation: - Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
- MedStar Health
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
|
